FCM
CORT icon

Flinton Capital Management’s Corcept Therapeutics CORT Stock Holding History

Flinton Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-16,856
Closed -$188K – 895
2019
Q2 		$188K Buy
16,856
+1,092
+7% +$12.2K 0.01% 691
2019
Q1 		$185K Hold
15,764
– – 0.01% 688
2018
Q4 		$211K Buy
15,764
+1,260
+9% +$16.7K 0.01% 638
2018
Q3 		$203K Buy
14,504
+3,976
+38% +$55.6K 0.01% 703
2018
Q2 		$166K Hold
10,528
– – 0.01% 688
2018
Q1 		$173K Buy
+10,528
New +$195K 0.01% 676

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Flinton Capital Management's CORT Position: Q3 2019 in Review

Flinton Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2019, closing a stake of 16,856 shares — an estimated $188K sold.

Flinton Capital Management first reported a position in CORT in Q1 2018 and held it in 6 quarters. The position peaked at $211K in Q4 2018. 193 funds tracked by Wall St. Rank hold CORT as of Q3 2019.

  • Flinton Capital Management reported no remaining Corcept Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Flinton Capital Management sold 16,856 Corcept Therapeutics shares in Q3 2019, an estimated $188K.
  • Flinton Capital Management first reported a position in Corcept Therapeutics in Q1 2018 and held it in 6 quarters.
  • Flinton Capital Management's Corcept Therapeutics position peaked at $211K in Q4 2018.
  • 193 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.